U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07011849) titled 'Phase 2 Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases' on June 02.
Brief Summary: This is a multi-center, open-label phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with renal cell carcinoma (RCC) and brain metastasis who were previously treated with immune checkpoint blockade.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Renal Cell Carcinoma
Brain Metastasis
Intervention:
DRUG: Pembrolizumab
Given by IV
DRUG: Lenvatinib
Given by mouth
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. And...